Welcome to our dedicated page for CIBUS SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cibus, Inc. (Nasdaq: CBUS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Cibus’ operations as an agricultural technology company that develops and licenses gene-edited plant traits to seed companies.
Through its recent Forms 8-K, Cibus has reported a range of material events, such as quarterly financial results and business updates, workforce reduction decisions, and the appointment of key executives and directors. For example, filings describe the appointment of a Chief Financial Officer under an executive employment agreement, the election of new board members with experience in technology, agriculture and finance, and actions to streamline the business by consolidating facilities and reducing headcount.
These filings also confirm that Cibus’ Class A common stock, with par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol CBUS. Investors reviewing the filings can see how the company describes its focus on productivity traits for major row crops, its reliance on licensing and royalty arrangements, and its assessment of risks and strategic alternatives as referenced in its periodic reports.
On Stock Titan, Cibus filings are supplemented with AI-powered summaries that help explain the key points of lengthy documents, such as current reports on Form 8-K or sections of annual and quarterly reports. Users can quickly identify items related to executive changes, cost structure adjustments, or updates to trait development programs, and then drill down into the full text for more detail. Real-time updates from EDGAR, combined with AI-generated highlights, make it easier to track CBUS regulatory disclosures, including insider-related items reported on Form 4 and the narrative and risk discussions contained in Forms 10-K and 10-Q.
Cibus, Inc. CFO Carlo Broos reported a small share disposition related to tax withholding. On this Form 4, 1,496 shares of Class A Common Stock were surrendered at $1.32 per share to cover tax obligations rather than sold on the open market. After this transaction, he directly holds 100,951 shares, so his overall ownership stake remains largely unchanged.
Cibus, Inc. senior vice president of research Noel Sauer reported two transactions in Class A common stock. On November 11, 2025, 1,834 shares were disposed of at $1.32 per share as a tax-withholding transaction, rather than an open-market trade. Earlier, on June 13, 2025, Sauer completed a small open-market sale of 4 shares at $1.485 per share. Following these transactions, Sauer directly holds 103,642 shares of Cibus Class A common stock.
Cibus, Inc. executive Jason Stokes, the company’s CLO, General Counsel and Secretary, reported routine share dispositions tied to tax obligations. Across three Form 4 entries using code F, a total of 13,109 Class A common shares were withheld to cover taxes, and he now holds 114,560 shares directly after the most recent transaction.
Cibus, Inc. is an agricultural biotechnology company focused on gene-edited plant traits, built on its patented Rapid Trait Development System (RTDS) and "Trait Machine" process that edit seed companies’ elite germplasm. The business targets royalty-based licensing rather than selling seed itself.
The company prioritizes herbicide-tolerant Rice traits, where it estimates Potential Annual Addressable Royalties of over $200.0 million in the United States and Latin America, plus large long-term opportunities in Asia and India. It also advances sustainable ingredient programs such as biofragrances, including a collaboration with Procter & Gamble.
Cibus is streamlining operations to preserve cash, including workforce reductions completed in 2025 and March 2026, and expects cost reductions and facility consolidation to lower annual net cash usage to approximately $30.0 million or less during 2026. As of June 30, 2025, the aggregate market value of Class A shares held by non‑affiliates was 47,156,698 based on a $1.38 share price, and as of March 10, 2026, there were 69,196,122 Class A shares outstanding.
Cibus, Inc. reported continued heavy losses alongside commercial and regulatory progress. For the quarter ended December 31, 2025, revenue was $1.1 million while net loss widened to $31.9 million, reflecting $9.1 million of long‑lived asset impairment tied to winding down its Roseville, Minnesota facility.
Full‑year 2025 revenue was $3.6 million and net loss was $132.2 million, a substantial but still large loss compared with 2024, which included a major goodwill impairment. Cost‑saving initiatives reduced research and development and selling, general and administrative expenses year over year.
Cash and cash equivalents were $9.9 million at December 31, 2025. Including $19.8 million in net proceeds from a January 2026 public offering and expected savings, Cibus believes it can fund operations into late in the third quarter of 2026. The board and its financial advisor are evaluating strategic alternatives while the company advances its rice herbicide tolerance program, sustainable ingredients initiative, and broader gene‑editing trait pipeline.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of 7,319,174 Cibus Inc. Class A common shares, representing 13.9% of the class as of December 31, 2025.
FMR LLC holds sole voting and dispositive power over these shares. Abigail P. Johnson is a separate reporting person, with sole dispositive power over the same 7,319,174 shares but no voting power. The filing states the position is held in the ordinary course of business and not to influence control of Cibus.
Within this stake, Fidelity Growth Company Commingled Pool held 3,555,164 Cibus Class A shares, equal to 6.7% of the outstanding class at December 31, 2025. The filing is signed on behalf of both FMR LLC and Abigail P. Johnson under previously granted powers of attorney.
Cibus, Inc. director Jean-Pierre Jules Lehmann reported buying 666,666 shares of Class A common stock at $1.50 per share in an underwritten public offering that closed on January 30, 2026. After the purchase, he directly owned 699,156 shares and was deemed to beneficially own an additional 1,687,071 shares held by JPL Investments, SA. The transaction was approved by Cibus, Inc.’s board of directors under Rule 16b-3.
Cibus, Inc. director and 10% owner Rory B. Riggs purchased 333,333 shares of Class A Common Stock at $1.50 per share in a firm commitment underwritten public offering that closed on January 30, 2026. The purchase was approved by the board under Rule 16b-3. Following this transaction, he directly beneficially owned 14,916,640 shares, with additional indirect holdings of 23,807 shares held by the Rory Riggs Family Trust, where he is trustee with sole voting and dispositive power, and 20,974 shares held by his spouse.
Cibus, Inc. entered into an underwriting agreement with BTIG, LLC for a public offering of 13,333,333 shares of Class A common stock at $1.50 per share. The company expects net proceeds of about $17.8 million, or $20.5 million if BTIG exercises its 30-day option to buy up to 1,999,999 additional shares.
Members of the board of directors will purchase 1,000,000 shares at the offering price, and directors, executive officers and the company agreed to a 60-day lock-up on additional sales, subject to limited exceptions. BTIG will receive a 6.25% underwriting discount and reimbursement of documented expenses up to $150,000. The deal is expected to close on or about January 30, 2026, subject to customary conditions.
Cibus, Inc. is conducting a primary underwritten offering of 13,333,333 shares of Class A common stock at $1.50 per share, with gross proceeds of about $20.0 million and estimated net proceeds of approximately $17.8 million before any exercise of the underwriter’s option for 1,999,999 additional shares.
The company plans to use the cash mainly for working capital and general corporate purposes, including further development of its weed management traits in Rice and payment of accrued advisory fees, including about $2.4 million owed to Ducera. Members of the board are purchasing 999,999 shares at the public price, and CBUS remains listed on Nasdaq.
Cibus highlights significant dilution: its net tangible book value was $(4.04) per share as of September 30, 2025, and investors in this deal face immediate dilution of about $4.46 per share. The company had $23.9 million in cash and cash equivalents and $20.6 million in current liabilities as of that date, is targeting annual net cash usage of roughly $30 million in 2026, and warns that it still needs additional financing and could ultimately be forced to wind down through bankruptcy, potentially leaving shareholders with little or no recovery.